HUTCHMED (CHINA) LIMITED Form 6-K Summary (Nov 2025)

HUTCHMED announced a significant clinical development milestone via Exhibit 99.1:

• Enrollment Completed for the SAFFRON global Phase III trial.
• The trial tests the combination therapy of ORPATHYS® and TAGRISSO®.
• Target Population: Lung cancer patients who progressed after prior TAGRISSO® treatment and have MET overexpression/amplification.

This milestone advances a key combination therapy in HUTCHMED’s oncology pipeline toward potential future data readouts.

The filing was dated November 5, 2025, and certified